NEW YORK, July  31, 2026  (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Alnylam Pharmaceuticals, Inc. (&#34;Alnylam&#34; or the &#34;Company&#34;) (NASDAQ:ALNY). The

ALNY

ALNYLAM PHARMACEUTICALS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

ALNY Receives Securities Investigation Following Q2 Guidance Cut and 28% Drop

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>NEW YORK, July  31, 2026  (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Alnylam Pharmaceuticals, Inc. (&amp;#34;Alnylam&amp;#34; or the &amp;#34;Company&amp;#34;) (NASDAQ:ALNY). The</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>ALNY&#039;s Q2 2026 results prompted a roughly $200 million cut to TTR net product revenue guidance, triggering a 28% stock decline. A securities investigation by Kirby McInerney LLP adds legal risk, though no lawsuit has been filed yet. The development raises near-term volatility and potential valuation pressure until clarity on potential claims emerges.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kirby McInerney LLP investigates ALNY for potential securities violations.</li><li>ALNY lowers 2026 TTR revenue guidance by about $200 million.</li><li>ALNY shares fell 28% to $205.48 on July 30, 2026.</li><li>No lawsuit filed yet; investigation ongoing.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Alnylam Pharmaceuticals, Inc. (ALNY)</strong>: Subject of a securities investigation; potential impact on governance, liability, and valuation.</li><li><strong>Kirby McInerney LLP (N/A)</strong>: Lead plaintiff law firm initiating inquiry; could be a catalyst if claims are filed.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. The piece centers on a securities investigation into ALNY, which could affect governance risk, cost of capital, and valuation. While no lawsuit is filed yet, the risk is meaningful for near-term price action and investor due diligence.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Securities investigation into ALNY raises near-term valuation and volatility risk.</li><li>Q2 miss and $200M TTR revenue reduction contributed to the share decline.</li><li>No formal lawsuit yet; ongoing uncertainty could weigh on sentiment.</li><li>ATTR-CM market dynamics remain a factor for long-term recovery.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date: July 30, 2026 — ALNY Q2 2026 results announced.</li><li>TTR net product revenues guidance reduced by about $200 million for 2026.</li><li>Shares closed at $205.48 on July 30, 2026, down ~28%.</li><li>Kirby McInerney LLP announced an investigation into ALNY for potential securities violations.</li><li>As of the release, no securities lawsuit had been filed; investigation ongoing.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term downside risk from a pending securities investigation; downside may persist until legal clarity, with potential rebound if no filing or favorable settlement within 1–3 quarters.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">NEW YORK, July  31, 2026  (GLOBE NEWSWIRE) -- The law firm of <a href="https://www.globenewswire.com/Tracker?data=tudW-LSCFTvKk6N705EVUpe3x96bgaGmUUIA6YERz6mD4SShN7gmFWb4kcqSIM_PfTOXfXXXx617auBnJN-hWA6nR00rr4X2YYfzUu-aiHE=" rel="nofollow" target="_blank">Kirby McInerney LLP</a> is investigating potential claims against Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ALNY">ALNY</a>). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.</p>  <p align="center">[<a href="https://www.globenewswire.com/Tracker?data=mKRJLtFr3kdVSZ93ErC4DUAWTVyLN5OKh4d8v-svyb3i1FMdjV5__nQbaPiKggvL_MPimp_IkzhTPXbe0-ZXrXaJURYf0I0ZbxMsS_QLyE_4Be1RhwPz-eAqYw7mo66WHD1NHpss_BK4Tx4Me-3EoWXHDe0NapJ4qhp89wmVekyyYJhtn1e-Ak_hpXzXPYyf" rel="nofollow" target="_blank">LEARN MORE ABOUT THE INVESTIGATION</a>]</p>  <p align="justify"><strong>What Happened?</strong></p>  <p align="justify">On July 30, 2026, Alnylam announced second quarter 2026 financial results. Among other things, the Company reported it has "lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy." As a result, the Company lowered its total projected TTR net product revenues by approximately $200 million.</p>  <p align="justify">On this news, shares of Alnylam fell $81.14 per share, or approximately 28%, to close at on $205.48 per share July 30, 2026.</p>  <p align="justify"><strong>What Should I Do?</strong></p>  <p align="justify">At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.</p>  <p align="justify">If you purchased or otherwise acquired Alnylam securities, have information, or would like to learn more about this investigation, please contact <a href="https://www.globenewswire.com/Tracker?data=2YxH8ZNK8nFqiS4JQ6MX0auYGvbx1yReGm_Yt3UFLuXjVzXAgcMcm-E-arxd98TUwSwsH4-pbhcn5Oq3ofB4e0P-pbPMJ8zD9v-UTeSA-W4Tgjyi5sfPOgHbIhPywq2S" rel="nofollow" target="_blank">Lauren Molinaro</a> of <a href="https://www.globenewswire.com/Tracker?data=tudW-LSCFTvKk6N705EVUlZgdu0YdZBwZf9pTflq7BYqrtJLlxylymLyvIddI5tEcpyn4qE0xlhU4aSP7W4CdDlOnZfGoMRVGEejfb7ndg8=" rel="nofollow" target="_blank">Kirby McInerney LLP</a> by email at <a href="https://www.globenewswire.com/Tracker?data=vta3nl62cCc6_Q-HhCksaMXFMOxGbmbJQfpq9sl--CP-jDLGJyQ27oEMHcSgjVW-NUf2X3WQnxFjbTV39T5pk78uuswunU6E2ewCPOvUmVBGkP33gArBTZD7SqdNDgFZ" rel="nofollow" target="_blank">investigations@kmllp.com</a>, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.</p>  <p align="center">[<a href="https://www.globenewswire.com/Tracker?data=mKRJLtFr3kdVSZ93ErC4DTCxmdVhl0eAn-z1kzkxnLMN2NNncxS4yRt26uDZbxfqV_QzkVicrXTOsTi9n-bjdaLKQ7seKaLo0Vqio2JO47CAhQDh11IEEo5HwfjI5C3mlgCUboV96fyr0_Hc0ansKA==" rel="nofollow" target="_blank">LEARN MORE ABOUT SECURITIES CLASS ACTIONS</a>]</p>  <p align="justify"><a href="https://www.globenewswire.com/Tracker?data=tudW-LSCFTvKk6N705EVUks5xej5p0y8mIIi9Y4cOXx4Vg6jhoKjijxCFg4lZpyvyAuHzmOOphwDgR39qXej1hZT8M3Akily4UPbrWDfDqc=" rel="nofollow" target="_blank">Kirby McInerney LLP</a> is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s <a href="https://www.globenewswire.com/Tracker?data=zFXgPsvnMtrJ__1GNKdGwI6wpw9_W5zWLP9s60orJd-CdeMyLbZTboanRumA1rSHAuvG86TcCV06-ise1f9i9A==" rel="nofollow" target="_blank">website</a>.</p>  <p align="justify">This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.</p>  <p align="justify">Contacts<br></br>Kirby McInerney LLP        <br></br>Lauren Molinaro, Esq.<br></br>212-699-1171<br></br><a href="https://www.globenewswire.com/Tracker?data=Pt0Vv3rwOJc0LPshzYrnXuQ4wmebrkavV8rGWz8ZOttkm_ds4rUCo6KMtD2hs1fkix3637uT2b-ZKoGVJDumjo1WObCJ3B0sxgMg3RCzWv8=" rel="nofollow" target="_blank">https://www.kmllp.com</a><br></br><u><a href="https://www.globenewswire.com/Tracker?data=Pt0Vv3rwOJc0LPshzYrnXkF0R-rVuaK38bCFcQ2wFh2EVXRrVotKJkvQKtN0n70oNl8I-8hOczE6UUW6X0e0sXjsGWvlgsAKW6L0adF9nbNJ5507J2pfTS8ywHKtBwUYdbYXXbfQYJfQbUpMdjvmtg==" rel="nofollow" target="_blank">https://securitiesleadplaintiff.com/</a></u><br></br><a href="https://www.globenewswire.com/Tracker?data=vta3nl62cCc6_Q-HhCksaMXFMOxGbmbJQfpq9sl--CPLbNLP7nL0_TMMX7u5Ay2qqT9KiuPQ43Gi1gdK34Gqf2LCoIDlLt-USst9V6cxhZTob9yhNc_ccS_Tj1qb7r5M" rel="nofollow" target="_blank">investigations@kmllp.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgwMTk1MyM3NzU0MTAyIzIwMjA2Njk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/M2Q3NTBmMmQtMDMxYi00MDVhLTg5YTctYmRlZTNmZDgwOTRlLTEwMzE5OTctMjAyNi0wNy0zMS1lbg==/tiny/Kirby-McInerney-LLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/192da1d1-643f-4eee-b850-dde5b9f2b00f"><img src="https://ml.globenewswire.com/media/192da1d1-643f-4eee-b850-dde5b9f2b00f/small/linkedin-logo-300x300-png.png" border="0" width="147" height="147" alt="Primary Logo"></img></a></p>

ALNY's Q2 2026 results prompted a roughly $200 million cut to TTR net product revenue guidance, triggering a 28% stock decline. A securities investigation by Kirby McInerney LLP adds legal risk, though no lawsuit has been filed yet. The development raises near-term volatility and potential valuation pressure until clarity on potential claims emerges.

News insight

ALNYLAM PHARMACEUTICALS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

AI summary

Sentiment rationale

Key facts

Legal